# Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC

> **NCT01742767** · PHASE2 · UNKNOWN · sponsor: **Universität Duisburg-Essen**

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Cisplatinum
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT01742767
- **Lead sponsor:** Universität Duisburg-Essen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-11
- **Primary completion:** 2014-05
- **Final completion:** 2015-04
- **Target enrollment:** — (—)
- **Last updated:** 2012-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01742767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01742767, "Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01742767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*